Description

Mobile Care Health’s Tirzepatide Microdosing Subscription is a clinician-guided low-dose GLP‑1 care—built for monitoring, tolerability, and transparency.

A provider-guided approach that may start at a lower dose than typical titration schedules, with individualized adjustments based on clinical evaluation and monitoring. Unlike traditional GLP-1 escalation protocols.

Each monthly plan includes compounded tirzepatide combined with Glycine (recovery, insulin sensitivity, and cardiometabolic support), tailored to your individual goals, by a licensed provider. Book your initial consultation here.

Microdosing GLP-1/GIP therapies may help:

• Improve glycemic control, stable blood glucose levels, and blood pressure support

• Reduction in visceral fat and waist circumference

• Potential improvements in lipid profiles

• Reduce systemic inflammation markers associated with cardiometabolic disease

• Glycine → amino acid that supports protein synthesis, endothelial function, and insulin sensitivity

• Reduce cardiovascular risk factors such as insulin resistance and central adiposity

Whats Included

• Monthly compounded tirzepatide + glycine (Up to 3mg/week) or 2ml tirzepatide with B12 every 2 months with labs

• Rewards membership with free shipping and 5% discount

• Personalized microdosing protocol

• Ongoing provider oversight with labs every six months

This is not an FDA-approved ‘microdosing’ regimen; evidence for very small doses is limited, and this is not a DIY program.

Compounded medications are prepared by a state-licensed pharmacy for an individual patient pursuant to a prescription and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) for safety, effectiveness, or quality.

FDA-approved medications in this class are available. Your provider will determine whether this therapy is appropriate for you and discuss all available options. Read our FAQs here.

Results vary. This program requires medical evaluation, ongoing monitoring, and adherence to lifestyle recommendations.

Additional information